Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Sopungsungi-won (SP) Prevents the Onset of Hyperglycemia and Hyperlipidemia in Zucker Diabetic Fatty Rats

  • Kim, Youn-Young (Laboratory of Pharmacology, School of Pharmacy, Kyung Hee University) ;
  • Kang, Hyo-Joo (Laboratory of Pharmacology, School of Pharmacy, Kyung Hee University) ;
  • Ko, Sung-Kwon (Korea Ginseng Institute, Chung-Ang University) ;
  • Chung, Sung-Hyun (Laboratory of Pharmacology, School of Pharmacy, Kyung Hee University)
  • Published : 2002.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Sopungsungi-won (SP) is a known for\mula for senile constipation and diabetes mellitus, based on traditional Korean medicine. The preventive effect of SP on the development of overt diabetes in Zucker diabetic fatty (ZDF) rats was evaluated. When administered orally through a diet for 8 weeks, diabetic conditions such as hyperglycemia, polydipsia and hypertriglyceridemia were all ameliorated in SP-treated rats. In parallel with the onset and progression of hyperglycemia in the ZDF control rats; there was a marked decline in plasma insulin concentrations from 26.1 $\mu$U/ml, at age 7 weeks, to 14.8 $\mu$U/ml at age 15 weeks. In the SP-treated rats, however, the plasma insulin concentrations did not decline, and SP at a dose of 5 g/kg significantly increased the insulin levels to 31.9 $\mu$U/ml. Early normalization of plasma insulin and a retained ability to subsequently increase plasma insulin were indicative of a pancreatic $\beta$ cell protective action by the SP for\mula. In addition, expressions of an insulin-responsive gene and corresponding protein, glucose transporter 4 (GLUT4), in skeletal \muscle, were also determined in SP- and rosiglitazone-treated ZDF rats. mRNA and protein levels of GLUT4 in SP-treated rats were upregulated in a dose dependent manner. Furthermore, when ZDF rats were treated with 2 g/kg of the SP for\mula, the activity of glucose-6-phosphatase was decreased by 49%, whereas the activity of glucokinase was increased by 196%, compared to the ZDF control rats. Taken together, these data provide evidence that the SP for\mula markedly lowered the plasma glucose levels, probably through an effect not only on improvement of insulin action, but through a combined sti\mulation of glycolysis and an inhibition of gluconeogenesis in the liver, and also suggest the validity of SP's clinical use in the treatment of type 2 diabetes mellitus following further toxicological investigation.

Keywords

References

  1. Amos, A. F., McCarty, D. J. and Zimmet, P., The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Medicine, 14, S1-S85 (1997)
  2. Baginski, E. S., Foa, P. P and Zak, B., 'Methods of enzymatic analysis,' Vol 2, ed. By H.U. Bergmeyer, Academic Press, NewYork and London, p. 876 (1974)
  3. Boil, G., Compagnucci, P., Cartechini, M.G., Santeusanio, F., Cirotti, C., Scionti, L. and Brunetti, P, HbA, in subjects with abnormal glucose tolerance but normal fasting plasma glucose. Diabetes, 29, 272-277 (1980) https://doi.org/10.2337/diabetes.29.4.272
  4. Defronzo, R. A., Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Reviews, 5, 177-269 (1997)
  5. Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E. and DeFronzo, R. A., Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J. Clin. Invest., 84, 205-213 (1989) https://doi.org/10.1172/JCI114142
  6. Hara, H., Miwa, I. and Okuda, J., Inhibition of rat glucokinase by alloxan and ninhydrin. Chem. Pharm. Bull., 34, 4731-4737 (1986) https://doi.org/10.1248/cpb.34.4731
  7. Kasiske, B. L., ODonnell, M. P., Cleary, M. P. and Keane, W. F., Treatment of hyperlipidemia reduces glomerular injury in obese Zuckerrats. Kidney International, 33, 667-672 (1998) https://doi.org/10.1038/ki.1988.51
  8. Klein, R, Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care, 18, 258-268 (1995) https://doi.org/10.2337/diacare.18.2.258
  9. Lee, S H., An, S. Y, Du, H. K. and Chung, S. H., Blood glucose loworing activity and mechanism of Sopungsungi-won (SPSGW) in dbldb mouse. J. Appl. Pharmacol., 7, 335-341 (1999)
  10. Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J., Protein Measurement with the Folin Phenol reagent. J. Biol. Chem., 193, 265-275 (1951)
  11. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treecher, D. F. and Turner, R. C., Homeostasis model assessment: insulin resistance and $\beta$-cell function from fasting plasma qlucose and insulin concentration in man. Diabeto-logia, 23, 412-419 (1985)
  12. Nathan, D. M., Long-term complications of diabetes mellitus. The New England Journal of Medicine, 328, 1676-1685 (1993) https://doi.org/10.1056/NEJM199306103282306
  13. Oakes N. D., Kennedy, C. J., Jenkins, A. B., Laybutt, D. R., Chisholm, D. J. and Kraegen, E. W., A new antidiabetic agent, BRL 4965, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes, 43, 1203-1211 (1994) https://doi.org/10.2337/diabetes.43.10.1203
  14. Polonsky, K. S., Sturis, J. and Bell, G. I., Non-insulin dependent diacates mellitus. A genetically programmed failure of the B cell :o compensate for insulin resistance. The New England Journal of Medicine, 334, 777-783 (1996) https://doi.org/10.1056/NEJM199603213341207
  15. Randle, P. J., Hales, C. N., Garland, P. B. and Newsholme, E. A., The glucose fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet, 13, 7285-7290 (1963)
  16. Seoane, J., Barbera, A., Telemaque-Potts, S., Newgard, C. B. and Guinovart, J. J., Glucokinase overexpression restores glucose utilization and storage in cultured hepatocytes from male Zucker diabetic fatty rats. J. Biol. Chem., 272, 31833-31838 (1999)
  17. Shimizu, H., Tsuchiya, T., Sato, N., Shimomura, Y, Kobayashi, I. and Mori, M., Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care, 21, 1470-1474 (1998) https://doi.org/10.2337/diacare.21.9.1470
  18. UK Prospective Diabetes Study Group, UK Prospective Diabetes Study 16. Overview of 6 tears therapy of type II diabetes: a progressive disease. Diabetes, 44, 1249-1258 (1995) https://doi.org/10.2337/diabetes.44.11.1249
  19. UK Prospective Diabetes Study Group, Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837-853 (1998) https://doi.org/10.1016/S0140-6736(98)07019-6
  20. Wajima, T., 'Rinsyo Kagaku Bunseki,' Vol 5, ed. By M. Kitamura, M. Satio, and M. Niwa, Tokyo Kagaku Dojin, Tokyo, p. 116 (1973)
  21. Wang, Q., Dryden, S. and Frankish, H.M., Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y. Br. J. Pharmacol., 128, 1405-1410 (1997)